Table 2.
Clinical actionability in the 31 IDH-wt GBMs of which the Molecular Tumor Board reviewed the results of CGPT.
| No. | ID (in this Cohort) |
CGPT | Diagnosis | Age | Gender | Acctionable Gene Aberration | Therapeutic Agents | Drug Type |
|---|---|---|---|---|---|---|---|---|
| 1 | 58_GBM | F-One | GBM, IDH-wt | 40 | M | BRAF V600E | Dabrafenib/Trametinib | clinical trial |
| 2 | 63_GBM | F-One | GBM, IDH-wt | 62 | F | BRAF V600E | Dabrafenib/Trametinib | clinical trial |
| 3 | 65_GBM | F-One | GBM, IDH-wt | 52 | F | BRAF V600E | Dabrafenib/Trametinib | clinical trial |
| 4 | 71_GBM | F-One | GBM, IDH-wt | 55 | F | FGFR1 K656E | FGFR inhibitor | Investigational drug * |
| 5 | 87_GBM | F-One | GBM, IDH-wt | 59 | M | FGFR3 FGFR3-TACC3 fusion | FGFR inhibitor | Investigational drug * |
| 6 | 101_GBM | F-One | GBM, IDH-wt | 59 | F | MSH6 C694fs*4, MSH6 I795fs*15 | Pembrolizumab | clinical trial * |
| 7 | 111_GBM | F-One | GBM, IDH-wt | 53 | M | FGFR3 FGFR3-TACC3 fusion | FGFR inhibitor | Investigational drug * |
Seven patients could be assigned to at least one clinical trial. Off-label use: use of the therapeutic agent within the coverage of public health insurance that is already approved for other tumors; however, not yet approved for glioma. GBM: glioblastoma, CGPT: comprehensive genomic profiling test, F-One: FoundationOne® CDx Cancer Genomic Profile, wt: wildtype, (*): enrollment in a clinical trial is pending, considering other therapeutic options.